De Graeve D, Lescrauwaet B, Nonneman W
Study Center for Economic and Social Research, University of Antwerp, Belgium.
Health Policy. 1997 Feb;39(2):93-106. doi: 10.1016/s0168-8510(96)00866-4.
The study calculates inpatient costs generated at the University Hospital in Antwerp (Belgium) and outpatient costs generated at the Institute of Tropical Medicine or at the University Hospital of 213 seropositive patients without AIDS and of 48 AIDS patients, for the year 1991. Outpatient drug use other than Zidovudine was excluded. An HIV + patient has an average annual total billing cost of 2062 ECU, 43% of which is spent in hospital, 29% on Zidovudine and 28% for follow-up at the Institute of Tropical Medicine. The average cost of care for an AIDS patient is 5.5 times higher and amounts to 11,277 ECU--hospitalisation costs (8349 ECU) and costs of Zidovudine (2031 ECU) are much higher. Costs vary with the severity of illness. In comparison to 1987, costs decreased due to lower drug prices and reduced hospitalisations. Life time costs of a seropositive patient are estimated at about 35,000 ECU, based on cost calculations per CD4-class for a follow-up period from 1991 to 1993.
该研究计算了1991年比利时安特卫普大学医院产生的住院费用，以及热带医学研究所或大学医院中213名无艾滋病血清阳性患者和48名艾滋病患者产生的门诊费用。齐多夫定以外的门诊药物使用情况被排除在外。一名HIV阳性患者的年均总计费成本为2062欧洲货币单位，其中43%用于住院，29%用于齐多夫定，28%用于在热带医学研究所的随访。一名艾滋病患者的平均护理成本高出5.5倍，达到11277欧洲货币单位——住院费用（8349欧洲货币单位）和齐多夫定费用（2031欧洲货币单位）要高得多。成本因疾病严重程度而异。与1987年相比，由于药品价格降低和住院次数减少，成本有所下降。根据1991年至1993年随访期间按CD4类别计算的成本，血清阳性患者的终身成本估计约为35000欧洲货币单位。
